Aberrant expression of KPNA2 is associated with a poor prognosis and contributes to OCT4 nuclear transportation in bladder cancer
Metrics: PDF 1939 views | HTML 1968 views | ?
Jingcheng Zhou1, Daoquan Dong1, Ran Cheng1, Yan Wang1, Shuqi Jiang2, Yuhong Zhu1, Longlong Fan1, Xiangming Mao1, Yaoting Gui2, Zesong Li4, Xianxin Li1,2,3, Bentao Shi1
1Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China
2Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, China
3Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, Guangdong 518112, China
4Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People’s Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China
Bentao Shi, email: [email protected]
Xianxin Li, email: [email protected]
Keywords: KPNA2, OCT4, bladder cancer, prognostic, nucleo-cytoplasmic transport
Received: July 20, 2016 Accepted: August 31, 2016 Published: September 07, 2016
Recent studies show that Karyopherin alpha 2 (KPNA2) is up-regulated in quite a number of cancers and associated with poor prognosis. Here, we found that expression levels of KPNA2 and OCT4 are up-regulated in bladder cancer tissues and significantly associated with primary tumor stage and bladder cancer patients’ poorer prognosis. Our data also showed decreased cell proliferation and migration rates of bladder cancer cell lines when the expression of KPNA2 and OCT4 was silenced. Meanwhile, cell apoptosis rate was increased. Furthermore, Co-IP and immunofluorescence assay showed the KPNA2 interacts with OCT4 and inhibits OCT4 nuclear transportation when KPNA2 was silenced. Thus, we confirmed that up-regulated KPNA2 and OCT4 expression is a common feature of bladder cancer that is correlated with increased aggressive tumor behavior. Also, we propose that KPNA2 regulates the process of OCT4 nuclear transportation in bladder cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.